Siegert R J, Abernethy D A
Rehabilitation Teaching and Research Unit, Department of Medicine, Wellington School of Medicine, University of Otago, PO Box 7343, Wellington South, New Zealand.
J Neurol Neurosurg Psychiatry. 2005 Apr;76(4):469-75. doi: 10.1136/jnnp.2004.054635.
Several studies have reported high rates of depression in multiple sclerosis (MS) with a lifetime prevalence of approximately 50% and an annual prevalence of 20% not uncommon. Concern about the potential of new drug treatments to exacerbate or precipitate depression in MS has led to increased interest in the relation between MS and depression. This review on MS and depression identifies the following key issues: How common is depression in people with MS? Is depression in MS associated with lesions in specific regions of the central nervous system? Is there an increased risk of suicide in MS? Is there a higher than expected incidence of anxiety disorders in MS? Are fatigue and depressed mood related in MS? Is there a relation between depression and cognitive impairment in MS? Which psychosocial variables affect the development of depression in MS? Does treatment with interferon increase the risk of depression? How effective are treatments for MS patients with depression? Each of these issues is briefly reviewed with critical commentary, and some priorities for future research are suggested.
多项研究报告称,多发性硬化症(MS)患者的抑郁症发病率很高,终生患病率约为50%,年患病率为20%也并不罕见。对新药治疗可能加重或引发MS患者抑郁症的担忧,引发了人们对MS与抑郁症之间关系的更多关注。这篇关于MS与抑郁症的综述确定了以下关键问题:MS患者中抑郁症有多常见?MS患者的抑郁症是否与中枢神经系统特定区域的病变有关?MS患者的自杀风险是否增加?MS患者焦虑症的发病率是否高于预期?MS患者的疲劳与情绪低落有关吗?MS患者的抑郁症与认知障碍之间有关系吗?哪些社会心理变量会影响MS患者抑郁症的发展?使用干扰素治疗会增加抑郁症的风险吗?针对MS抑郁症患者的治疗效果如何?本文对上述每个问题进行了简要综述并给出批判性评论,并提出了一些未来研究的重点。